Treatment of recurrent prostate cancer following radical prostatectomy: The radiation-oncologists point of view

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 5, 2012, Pages 409-420

  Rischke, H C ^a   Knippen, S ^a   Kirste, S ^a   Grosu, A L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Magnetic resonance imaging; Prostatic neoplasms; Radiotherapy

Indexed keywords

ANTIANDROGEN; CHOLINE C 11; GADOLINIUM; PROSTATE SPECIFIC ANTIGEN; TRACER;

ANTIANDROGEN THERAPY; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DISTANT METASTASIS; GLEASON SCORE; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION SICKNESS; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; STEREOTACTIC RADIOSURGERY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; WHOLE BODY CT; WHOLE BODY PET;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY;

EID: 84871808651     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-10. (Pubitemid 27139819)
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23. (Pubitemid 36132976)
3. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-72.
4. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306. (Pubitemid 29434327)
5. Choo R. Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges. Cancer Research and Treatment: official journal of Korean Cancer Association 2010;42:1-11.
6. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231:379-85. (Pubitemid 38552892)
7. S Symon Z, Kundel Y, Sadetzki S, Oberman B, Ramon J, Laufer M et al. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models. Am J Clin Oncol 2006;29:446-50.
8. MacDonald OK, Schild SE, Vora S, Andrews PE, Ferrigni RG, Novicki DE et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology 2004;64:760-4. (Pubitemid 39446058)
9. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006;176:985-90. (Pubitemid 44160708)
10. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008;71:23-7.
11. Neuhof D, Hentschel T, Bischof M, Sroka-Perez G, Hohenfellner M, Debus J. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 2007;67:1411-7. (Pubitemid 46467172)
12. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163:845-50. (Pubitemid 30091629)
13. Sasaki T, Nakamura K, Shioyama Y, Ohga S, Toba T, Urashima Y et al. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer. Anticancer Research 2006;26:2367-74. (Pubitemid 43980203)
14. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. Journal of Clinical Oncology. Official Journal of the American Society of Clinical Oncology 2007;25:2035-41. (Pubitemid 46972788)
15. Bernard JR Jr, Buskirk SJ, Heckman MG, Diehl NN, Ko SJ, Macdonald OK et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. International Journal of Radiation Oncology, Biology, Physics 2010;76:735-40.
16. King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? International Journal of Radiation Oncology, Biology, Physics 2008;71:346-50.
17. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. International Journal of Radiation Oncology, Biology, Physics 2011;81:1049-58.
18. Grosu AL, Nestle U, Weber WA. How to use functional imaging information for radiotherapy planning. Eur J Cancer 2009;45 Suppl 1:461-3.
19. Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2006;66:339-44. (Pubitemid 44332720)
20. Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Physics in Medicine and Biology 2009;54:R1-25.
21. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. Journal of Urology 1989;141:1076-83. (Pubitemid 19124201)
22. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996;47:225-31. (Pubitemid 26075278)
23. Deliveliotis C, Manousakas T, Chrisofos M, Skolarikos A, Delis A, Dimopoulos C. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World Journal of Urology 2007;25:309-13.
24. Naya Y, Okihara K, Evans RB, Babaian RJ. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology 2005;66:350-5. (Pubitemid 41138096)
25. Saleem MD, Sanders H, Abu El Naser M, El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998;51:283-0.
26. Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P et al. Diagnosis of local recurrence after radical prostatectomy. BJU international 2004;93:680-8. (Pubitemid 38375788)
27. Shekarriz B, Upadhyay J, Wood DP Jr, Hinman J, Raasch J, Cummings GD et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology 1999,54:1044-8.
28. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387-98. (Pubitemid 44885404)
29. Reske SN, Blumstein NM, Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008;35:9-17. (Pubitemid 350234137)
30. Dotan ZA, Bianco FJ Jr, Rabbani F, Eastham JA, Fearn P, Scher HI et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2005;23:1962-8. (Pubitemid 46211375)
31. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKernion JB et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004;171:2260-4. (Pubitemid 38625447)
32. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23. (Pubitemid 350234152)
33. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiologia Medica 2008;113:895-904.
34. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253-63.
35. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:301-9.
36. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C et al. Is there a role for (1)(1)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/mL? Eur J Nucl Med Mol Imaging 2011;38:55-63.
37. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394-400.
38. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L et al. PSA doubling time for prediction of [(11)C] choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:1106-16.
39. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 1997;168:379-85. (Pubitemid 27051968)
40. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging-initial experience. Radiology 2004;233:709-15.
41. Futterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergenvan De Kaa CA, Witjes JA, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005;237:541-9. (Pubitemid 41507892)
42. Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-58. (Pubitemid 44632891)
43. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008;190:1187-92. (Pubitemid 351684918)
44. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54:589-600.
45. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19:761-9.
46. Rischke HC, Nestle U, Volegova-Neher N, Henne K, Schäfer AO, Schultze-Seemann W, Detecting local recurrent prostate cancer: MRI patterns of post-prostatectomy recurrence and of its response to salvage radiotherapy using Dynamic Contrast Enhanced (DCE) MRI. Strahlenther Onkol 2011;187(Sondernr 1):43.
47. Miralbell R, Vees H, Lozano J, Khan H, Molla M, Hidalgo A et al. Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 2007;67:356-61. (Pubitemid 46108320)
48. Choo R, Hruby G, Hong J, Bank E, Hong E, Danjoux C et al. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002;53:269-76. (Pubitemid 34522092)
49. Choo R, Morton G, Danjoux C, Hong E, Szumacher E, DeBoer G. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery. Radiother Oncol 2005;74:163-7. (Pubitemid 40331873)
50. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005,294:433-9. (Pubitemid 41124175)
51. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-9. (Pubitemid 351846851)
52. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol 2009;182:2708-14.
53. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA et al. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys 2009;75:983-9.
54. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21:483-9. (Pubitemid 46606478)
55. King CR, Presti JC, Jr., Gill H, Brooks J, Hancock SL. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys 2004;59:341-7. (Pubitemid 38622584)
56. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 2003;56:755-63. (Pubitemid 36677369)
57. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-32. (Pubitemid 38541647)
58. Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 2012;48:837-44.
59. Cozzarini C, Fiorino C, Da Pozzo LF, Alongi F, Berardi G, Bolognesi A et al. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys 2012;82:191-9.
60. De Meerleer G, Fonteyne V, Meersschout S, Van den Broecke C, Villeirs G, Lumen N et al. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol 2008;89:205-13.
61. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27(18):2924-30.
62. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25:4178-86. (Pubitemid 47548556)
63. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Trover D et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956-62.
64. Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev 2011;12:CD007234.
65. Teh BS, Woo SY, Butler EB. Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology. Oncologist 1999;4:433-42. (Pubitemid 30013177)
66. Wiehle R, Knippen S, Grosu AL, Bruggmoser G, Hodapp N. VMAT and Step-and-Shoot IMRT in Head and Neck Cancer: A Comparative Plan Analysis. Strahlenther Onkol 2011;187:820-25.
67. Yu CX. Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy. Phys Med Biol 1995;40:1435-49.
68. Guckenberger M, Meyer J, Vordermark D, Baier K, Wilbert J, Flentje M. Magnitude and clinical relevance of translational and rotational patient setup errors: a cone-beam CT study. Int J Radiat Oncol Biol Phys 2006;65:934-42. (Pubitemid 43795840)
69. Kirste S, Volegova-Neher N, Henne K, Knippen S, Rischke HC, Schäfer AO et al. Dose escalated radiotherapy of macroscopic local recurrence after radiacal prostatectomy. Strahlenther Onkol 2011;187(Sondernr 1):112.
70. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Actas Urol Esp 2011;35:565-79.
71. Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55:261-70.
72. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011;60:935-43.
73. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:889-97.